Skip to Navigation

Amitava Chattopadhyay


Amitava Chattopadhyay
Emerging Market Multinationals - Amitava Chattopadhyay


Ranbaxy Laboratories Limited: At the Crossroads

Ranbaxy Laboratories Limited: At the Crossroads

 

 

The case describes the challenges facing Ranbaxy, the third largest pharmaceutical company in India, which has set itself the goal of moving from the branded generic space to the greater value added branded pharmaceutical space. It has developed a one-a-day delivery system for ciprofloxacin a widely used antibiotic that is about to go off patent. Having sold the rights for the drug delivery system for markets outside India and the CIS to Bayer, the inventor of ciprofloxacin, Ranbaxy is wondering how it should market this new formulation in the India market in particular.


Teaching Objectives

The case poses several interesting questions. First, how should the one-a-day formulation of ciprofloxacin, to be called Cifran OD in India, be positioned? Ranbaxy currently markets ciprofloxacin under the name of Cifran as a branded generic in India. Should Cifran be discontinued when Cifran OD is launched? How should the Cifran OD positioning be implemented? Should the OD formulation be marketed by Ranbaxy alone or should it be co-marketed in collaboration with other local and global pharmaceutical players? The latter question facilitates an interesting discussion of when and how should one collaborate with competitors.

The case has been used for both MBA and executive audiences. It can be used in an introductory marketing course to highlight the power of good positioning. It can also be used in a course on pharmaceutical marketing or a course on how companies from emerging markets can climb the value added business ladder.



Download PDF


 

  Nov 1, 2003 | Cases




Download PDF



SHARE


 


Recent Tweets



Thu, 01 Dec @ 07:54 am

@MaryLTrump More disrespect would be even better. He should be locked up. Nothing but a fraud.

via Twitter for Android
Thu, 01 Dec @ 07:53 am

RT @MaryLTrump: The disrespect being shown to Donald by Georgia Republicans is beyond the pale. Let the man campaign for the other most inc…

via Twitter for Android
Fri, 25 Nov @ 06:17 pm

Couldn't resist a walk in the forest this afternoon. It was perfect. Cold, but not too cold, and the forest bathed… https://t.co/99pT2hSt7M

via Instagram
Thu, 24 Nov @ 09:51 pm

No problem. It's his story. Make it up & public who wants to hear of glory will lap it up. Will keep BJP in power l… https://t.co/2oRFKG6EDc

via Twitter for Android
Wed, 23 Nov @ 05:24 pm

Goldman says growth 5.9%, Niti Aayog 7%. #GautamAdani: India $30tr economy by 2050. #MukeshAmbani says $40tr! Is th… https://t.co/jKEzwdwyxq

via Twitter for Android
Sat, 19 Nov @ 04:08 pm

1$tr/yr! Math doesn't add up when we look @ GDP growth. Require growing at 2X current rate. Likely hot air from a… https://t.co/kRCxvjfRSV

via Twitter for Android

  Close About Papers Cases Books Teaching Musings Media Gallery Ask Amitava